Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 64,331 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $0.83, for a total transaction of $53,394.73. Following the completion of the transaction, the insider owned 5,257,105 shares of the company’s stock, valued at $4,363,397.15. This trade represents a 1.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total value of $39,130.36.
• On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $87,025.96.
• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $62,344.56.
• On Tuesday, November 18th, Ansbert Gadicke sold 52,627 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $48,943.11.
• On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total value of $54,207.95.
• On Friday, November 14th, Ansbert Gadicke sold 61,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $57,325.20.
• On Thursday, November 13th, Ansbert Gadicke sold 90,951 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $89,131.98.
• On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $63,623.40.

Werewolf Therapeutics Trading Down 6.8%

HOWL traded down $0.07 during mid-day trading on Tuesday, reaching $0.91. The stock had a trading volume of 461,162 shares, compared to its average volume of 505,004. The firm’s fifty day simple moving average is $1.52 and its two-hundred day simple moving average is $1.34. The stock has a market capitalization of $44.19 million, a P/E ratio of -0.56 and a beta of 0.73. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Quadrature Capital Ltd bought a new stake in Werewolf Therapeutics in the 2nd quarter valued at approximately $28,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $48,000. Nuveen LLC acquired a new stake in shares of Werewolf Therapeutics in the first quarter valued at approximately $71,000. AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics in the first quarter valued at approximately $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics in the second quarter worth $92,000. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Bank of America cut their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities lowered their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Finally, Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.